Screener
NeoGenomics NEO Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001077183-26-000059
| Line item | (unaudited)June 30, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity | ||
| Common stock, $0.001 par value, (250,000,000 shares authorized; 130,301,168 and 128,989,152 shares issued, respectively; 127,917,946 and 128,989,152 shares outstanding, respectively) | $130 | $129 |
| Treasury stock, at cost, (2,383,222 and 0 shares, respectively) (Note 7) | (25,000) | — |
| Additional paid-in capital | 1,259,272 | 1,270,235 |
| Accumulated other comprehensive income | 4 | 4 |
| Accumulated deficit | (448,674) | (433,806) |
| Total stockholders' equity | $785,732 | $836,562 |
| Total liabilities and stockholders’ equity | $1,352,243 | $1,359,830 |
Item 1. Financial Statements (unaudited)
FAQ
- What is NeoGenomics's total equity?
- NeoGenomics (NEO) reported total equity of $785.73M in Q2 2026.
- How has NeoGenomics's total equity changed year-over-year?
- NeoGenomics's total equity decreased by 8.0% year-over-year, from $854.04M to $785.73M.
- What is the long-term trend for NeoGenomics's total equity?
- Over 5 years (2020 to 2025), NeoGenomics's total equity has grown at a 3.8% compound annual growth rate (CAGR), from $694.29M to $836.56M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about NeoGenomics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude